T Cell Activation by Antibody-Like Immunoreceptors: The Position of the Binding Epitope within the Target Molecule Determines the Efficiency of Activation of Redirected T Cells-Reference-Cited by-同舟云学术

T Cell Activation by Antibody-Like Immunoreceptors: The Position of the Binding Epitope within the Target Molecule Determines the Efficiency of Activation of Redirected T Cells

Published:2007-03-19 Issue:7 Volume:178 Page:4650-4657
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Hombach Andreas A.,Schildgen Verena,Heuser Claudia,Finnern Ricarda,Gilham David E.,Abken Hinrich

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference20 articles.

1. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

2. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?

3. The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy

4. T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition

5. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T Cell Therapy for Cancer;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-04-15

2. Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin;PLOS ONE;2024-04-04

3. Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer;Cancers;2024-01-16

4. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell;BMC Biotechnology;2024-01-04

5. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy;Immunity;2023-10